Compare Levi Strauss & Co. (LEVI) vs BIO-TECHNE Corp (TECH) Price & Performance

Levi Strauss (LEVI) trades at $24.03, down 1.35% over the past day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.28, exceeding expectations of $0.24, and raised its full-year outlook. Strong fundamentals include a 61.72% gross margin and 9.66% net income margin, supported by a digital strategy driving direct-to-consumer growth. Analyst consensus is overwhelmingly bullish with an 83.33% buy rating and a $28.00 price target, implying significant upside from current levels.

Outlook remains positive given earnings momentum and dividend increases, but risks include tariff pressures and foreign exchange volatility noted in recent reports. The stock's valuation at a P/E of 17.4 appears reasonable relative to profitability, though competitive and macroeconomic headwinds warrant monitoring for sustained growth.

Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.

The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.